Latest News for: chugai

Edit

NXT007 Suggests Favorable Tolerability and Efficacy in Phase I/II Study for Hemophilia A Following Direct Switch from Emicizumab without Washout Period (Chugai Pharmaceutical Co Ltd)

Public Technologies 09 Feb 2026
NXT007 is a Chugai-originated compound currently under development for hemophilia A ... TOKYO, February 9, 2026 -- Chugai Pharmaceutical Co., Ltd ... Osamu Okuda, Chugai's President and CEO ... Chugai Pharmaceutical Co.
Edit

Supplementary Materials [PDF 665KB] Supplementary Materials [Excel 255KB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 29 Jan 2026
Chugai shareholders ... Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results ... Chugai shareholders.
Edit

Full Year Results (Jan-Dec 2025) [PDF 1.2MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 29 Jan 2026
Chugai Pharmaceutical Co., Ltd ... 4519 (URL https.//www.chugai-pharm.co.jp/english) Representative ... Net income attributable to Chugai shareholders ... In preparing Chugai performance outlook, Chugai has assumed exchange rates of ¥184/CHF, ¥179/EUR,.
Edit

Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer (Chugai Pharmaceutical Co Ltd)

Public Technologies 28 Jan 2026
Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer ... TOKYO, January 28, 2026 -- Chugai Pharmaceutical Co., Ltd ... Chugai Pharmaceutical Co.
Edit

Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer (Chugai Pharmaceutical Co Ltd)

Public Technologies 28 Jan 2026
Preclinical results of ROSE12, an anti-CTLA-4 switch antibody engineered with Chugai's proprietary Switch-Ig technology, have been accepted by the Journal for ImmunoTherapy of Cancer, a leading journal in cancer immunotherapy.
Edit

Presentation [PDF 714KB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 15 Jan 2026
CHUGAI PHARMACEUTICAL CO., LTD ... This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd ... Chugai will not comment on undisclosed financial results ... Chugai products.
Edit

KRAS Inhibitors Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | Pfizer, Roche, Chugai, ...

GetNews 08 Jan 2026
The Key KRAS Inhibitors Companies in the market include - Pfizer, Roche/Chugai/Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, and Astex Pharmaceuticals, ... Roche/Chugai/Genentech.
Edit

Corporate Governance Report [PDF 1MB] (Chugai Pharmaceutical Co Ltd)

Public Technologies 24 Dec 2025
Please note that the following is an unofficial English translation of the Japanese original text of the Corporate Governance Report of CHUGAI PHARMACEUTICAL CO., LTD. (“Chugai” or the “Company”), which is reported to the Tokyo Stock Exchange.
Edit

Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Chugai Pharmaceutical Co Ltd)

Public Technologies 18 Dec 2025
). December 18, 2025 ... Chugai Pharmaceutical Co., Ltd ... TOKYO, December 18, 2025 -- Chugai Pharmaceutical Co., Ltd ... Orforglipron was discovered by Chugai, and Eli Lilly holds its exclusive development and commercialization rights ... Chugai Pharmaceutical Co.
Edit

Chugai Awarded Highest A-Ratings by CDP in Climate Change and Water Security (Chugai Pharmaceutical Co Ltd)

Public Technologies 17 Dec 2025
Chugai Awarded Highest A-Ratings by CDP in Climate Change and Water Security. fiOKYO, Dcccmdcr !7, 2025 -- Chugai Wharmaccu"icai Co., W"d ... Chugai's Sus"ainadiii"y. ... Chugai Pharmaceutical Co.
Edit

Chugai Opens U.S. Partnering Office in South San Francisco to Accelerate Global Open Innovation (Chugai Pharmaceutical Co Ltd)

Public Technologies 11 Dec 2025
Chugai Opens U.S ... With the establishment of Chugai Partnering US Office, Chugai will further strengthen this global partnering network and establish a comprehensive framework for worldwide partnership activities ... Chugai Partnering US Office.
Edit

Roche’s Announcement Regarding Giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast Cancer at SABCS) (Chugai Pharmaceutical Co Ltd)

Public Technologies 11 Dec 2025
). News Release. Roche's Announcement Regarding Giredestrant (Presentation of Latest Data in Estrogen Receptor Positive Breast. Cancer at SABCS). TOKYO, December 11, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO ... Disclaimer. Chugai Pharmaceutical Co. Ltd.
Edit

48-Week Phase III Results Presented at Japanese Retina and Vitreous Society Meeting Show that Vabysmo Sustained Vision Improvements in Japanese Patients with Angioid Streaks (Chugai Pharmaceutical Co Ltd)

Public Technologies 08 Dec 2025
TOKYO, December 8, 2025 -- Chugai Pharmaceutical Co., Ltd ... Chugai Files ... https.//www.chugai-pharm.co.jp/english/news/detail/20250417122000_1150.html About the NIHONBASHI study ... Chugai Pharmaceutical Co.
Edit

Renalys Pharma’s Announcement Regarding Sparsentan (Results of Domestic Phase III Study for IgA Nephropathy) (Chugai Pharmaceutical Co Ltd)

Public Technologies 26 Nov 2025
TOKYO, November 26, 2025 -- Chugai Pharmaceutical Co., Ltd ... (hereinafter "Renalys Pharma"), which Chugai is scheduled to acquire as a wholly-owned subsidiary on ... Chugai Pharmaceutical Co.
Edit

Port Delivery System with Ranibizumab Demonstrates Results Phase I/II Trial for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema in Japan (Chugai Pharmaceutical Co Ltd)

Public Technologies 25 Nov 2025
TOKYO, November 25, 2025 -- Chugai Pharmaceutical Co., Ltd ... Osamu Okuda, Chugai's President and CEO. Chugai will file a new drug application in Japan based on the study results, ... Chugai Pharmaceutical Co.

Article Search

tools
×
×
×
×